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Abstract
Background: Two randomised 12-week, double-blind, parallel-group, multicenter studies comparing oxycodone
PR/naloxone PR and oxycodone PR alone on symptoms of opioid-induced bowel dysfunction in patients with
moderate/severe non-malignant pain have been conducted.
Methods: These studies were prospectively designed to be pooled and the primary outcome measure of the
pooled data analysis was to demonstrate non-inferiority in 12-week analgesic efficacy of oxycodone PR/naloxone
PR versus oxycodone PR alone. Patients with opioid-induced constipation were switched to oxycodone PR and
then randomised to fixed doses of oxycodone PR/naloxone PR (n = 292) or oxycodone PR (n = 295) for 12 weeks
(20-80 mg/day).
Results: No statistically significant differences in analgesic efficacy were observed for the two treatments
(p = 0.3197; non-inferiority p < 0.0001; 95% CI -0.07, 0.23) and there was no statistically significant difference in
frequency of analgesic rescue medication use. Improvements in Bowel Function Index score were observed for
oxycodone PR/naloxone PR by Week 1 and at every subsequent time point (-15.1; p < 0.0001; 95% CI -17.3, -13.0).
AE incidence was similar for both groups (61.0% and 57.3% of patients with oxycodone PR/naloxone PR and
oxycodone PR alone, respectively).
Conclusions: Results of this pooled analysis confirm that oxycodone PR/naloxone PR provides effective analgesia
and suggest that oxycodone PR/naloxone PR improves bowel function without compromising analgesic efficacy.
Trial registration numbers: ClinicalTrials.gov identifier: NCT00412100 and NCT00412152
Background
Opioids are established treatment for moderate/severe
chronic malignant pain, as recommended by the World
Health Organization (WHO) [1]; furthermore, they are
the mainstay of treatment for chronic non-malignant
pain [2]. Oxycodone is a semi-synthetic, opioid that is
effective in alleviating malignant pain [3,4], postopera-
tive pain, osteoarthritis [5] and neuropathic non-malig-
nant pain [6-8].
Opioids exert their analgesic effects mainly by binding
to receptors within the central nervous system; however,
opioid receptors also reside within the gastrointestinal
(GI) tract [9]. Binding of opioids to these receptors
commonly leads to GI adverse events (AEs), including
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distension and gastric reflux that are collectively
known as opioid-induced bowel dysfunction[10].
Opioid-induced constipation (OIC) is the most fre-
quently reported AE in patients receiving opioids [2].
Unlike most side effects associated with opioids that
subside with chronic use, constipation often persists
and usually requires active management [11]. The pain
and discomfort caused by OIC can cause patients to
reduce or discontinue their opioids [9], resulting in
inadequate analgesia and poor quality of life; up to
30% of patients reduce or discontinue opioids due to
such problems [12].
Current management for OIC is nonspecific and often
ineffective [9]. Laxatives can improve symptoms in some
patients, although many do not achieve adequate relief
of symptoms [9,10]. In one survey, only 46% of patients
taking medication for OIC experienced improvement for
over 50% of the time compared with 80% of non-opioid
users taking similar medication for constipation [10].
This may be because laxatives do not counteract the
underlying opioid receptor-mediated mechanism of
OIC. Prevention of OIC, and bowel dysfunction, is
therefore a more effective strategy than treating it once
it occurs [9].
An emerging strategy for targeting the cause of OIC is
oral administration of opioid-receptor antagonists that
act specifically and locally within the GI tract. These
prevent or minimize adverse GI effects, but do not com-
promise central analgesic opioid effects because of their
limited systemic bioavailability. Naloxone is an opioid-
receptor antagonist that, when administered orally, has a
very low systemic bioavailability (< 3%) due to its exten-
sive first-pass hepatic metabolism, but acts on opioid
receptors within the GI tract [13].
Immediate-release (IR) oral naloxone was evaluated in
several studies to evaluate its ability to reduce OIC
[14-17]. However, results have been equivocal and in
some of these study results showed, that even low doses
of oral IR naloxone were causing withdrawal symptoms.
A prolonged-release (PR) formulation of oral naloxone
can reveal a reduction of these risks. The extensive
clinical development with the PR formulation of the
fixed-dose combination oxycodone (PR)/naloxone (PR)
confirmed the favourable efficacy and safety of this com-
bination also with respect to the withdrawal and analge-
sia [18-23].
Results from a study which compared pharmacoki-
netics data from a single-dose and multiple-dose bioe-
quivalence study of fixed-dose combination (FDC)
oxycodone prolonged-release (PR)/naloxone PR versus
separate formulations of oxycodone PR and naloxone
PR administered concurrently in healthy volunteers,
demonstrated that the co-administration of oxycodone
PR and naloxone PR in a FDC does not significantly
affect the bioavailability of either of its constituents [20].
Indeed, oral co-administration of oxycodone PR/nalox-
one PR in a 2:1 ratio provides effective analgesia for
patients with severe chronic pain while significantly
improving OIC [21]. A previous Phase III trial showed
that the fixed combination of oxycodone PR/naloxone
PR was superior to placebo in analgesic efficacy and
provided benefits with regard to bowel function. Analge-
sic efficacy of oxycodone PR/naloxone PR was compar-
able to that of oxycodone PR, which was included as an
active comparator. Therefore, the addition of naloxone
PR to oxycodone PR in the fixed combination did not
negatively impact the analgesic efficacy of the oxyco-
done component [19]. In addition, results from a pro-
spective non-interventional, 4-week observational study
which was designed to evaluate the efficacy and safety
of oxycodone PR/naloxone PR reported that this combi-
nation proved effective and safe in more than 7000
patients with severe pain of different aetiologies, includ-
ing those with severe cancer pain [24]. These findings
have been further corroborated in elderly patient sub-
groups and several long-term extension phases of clini-
cal trials [18,25,26]. Moreover, naloxone PR/oxycodone
PR has been shown to improve patient assessment of
analgesic opioid therapy for severe chronic pain, in
terms of both efficacy and tolerability [23].
Here, we present a prospectively planned pooled ana-
lysis of data from two Phase III studies that included
subjects with OIC [27,28]. Both studies were similar in
design and were conducted to compare the safety and
efficacy of the fixed combination of oxycodone PR/
naloxone PR (oxycodone PR 20-80 mg/day) compared
with oxycodone PR in the treatment of patients with
moderate-to-severe chronic non-malignant pain. The
primary focus of the pooled analysis was to examine the
analgesic efficacy of oxycodone PR/naloxone PR com-
pared with oxycodone PR alone during 12 weeks of
treatment.
Methods
This was a prospectively designed pooled analysis of
two randomised, double-blind, double-dummy, paral-
lel-group, multicenter, 12-week studies (OXN3001 and
OXN3006). Details of the designs of the two studies
have been published previously [27,28]. The primary
endpoint of the pooled data analysis was to demon-
strate the non-inferiority of oxycodone PR/naloxone
PR compared with oxycodone PR alone in terms of 12-
week analgesic efficacy in patients with moderate/
severe non-malignant pain; this was based on the
patients’ average pain over the previous 24 hours,
assessed at each double-blind study visit using the Pain
Intensity Scale.
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taining oxycodone PR doses of 20-80 mg/day. Secondary
objectives were to determine the frequency of rescue
medication used per day and to investigate the symp-
toms of constipation based on laxative intake and
patient bowel function self-assessment using the vali-
dated Bowel Function Index (BFI) [29]. Another second-
ary objective was to assess the safety of oxycodone PR/
naloxone PR and oxycodone PR. Exploratory analyses
included an assessment of overall health of the treat-
ment groups, using the Short-Form (SF)-36version 2
questionnaire [30,31] and the Treatment Satisfaction
Questionnaire (TSQM) [32].
The pooled analysis of the two studies was prospec-
tively planned to obtain a sample size providing
adequate statistical power to confirm analgesic non-
inferiority of oxycodone PR/naloxone PR and oxycodone
PR alone (primary endpoint). Furthermore, analysis of
the pooled data allows the exploration of the efficacy
and safety of the entire dose range of oxycodone PR/
naloxone PR compared with oxycodone PR. The studies
were conducted in accordance with the Declaration of
Helsinki (1964) and all of its accepted amendments to
date [33] as well as complying with the principles of
Good Clinical Practice set by the International Confer-
ence on Harmonization [34] and the European Union
Clinical Trials Directive (2001) [35]. Written informed
consent was obtained from all participants at screening.
Patient population
M a l e sa n df e m a l e sa g e d≥ 18 years were recruited into
the two studies if they had a documented history of
moderate/severe non-malignant pain that required con-
tinual opioid therapy (oxycodone equivalent of ≥ 20 mg/
day and ≤ 80 mg/day), had constipation that was caused
or aggravated by an opioid and were likely to benefit
from WHO step III opioid therapy for the duration of
the study [1].
The subject’s subjective assessment of their opioid-
induced constipation had to be confirmed at screening
by interviews performed by the investigator. In cases
where there was a close relationship between the opioid
intake and the occurrence/aggravation of constipation,
the existing constipation was regarded as caused or
aggravated by opioids. Furthermore a definition describ-
ing constipation caused or aggravated by opioids has
been developed based on the Rome II criteria [36] and
these criteria had to be fulfilled prior to randomisation.
Exclusion criteria included history of hypersensitivity
to oxycodone, naloxone, related products or other sub-
stances; any contraindication to bisacodyl or other sub-
stances in the study laxative; females who were pregnant
or lactating; patients with malignancy-related pain, rheu-
matoid arthritis or evidence of clinically unstable disease
or of impaired liver and/or kidney function at study
entry; evidence of significant structural abnormalities of
the GI tract; or any diseases/conditions that affected
bowel transit.
Study design
The studies consisted of a screening phase, and a pre-
randomisation phase followed by a double-blind phase
in which patients received the study medication for up
to 12 weeks (Figure 1). During the pre-randomisation
run-in phase, patients were switched to oxycodone PR
alone over 7 to 28 days, during which they were titrated
to an effective analgesic dose. Patients were also
switched to the standard laxative regimen using oral
bisacodyl and were permitted to use oxycodone immedi-
ate-release during the run-in phase.
At study baseline (Visit 3), all patients had achieved
stable pain control, had confirmed OIC and had satisfied
all other inclusion and exclusion criteria. Patients were
then randomised to double-blind study medication: oxy-
codone PR/naloxone PR (2:1 fixed-dose ratio) or oxyco-
done PR alone. Patients who received more than two
doses of rescue medication per day for persistent pain
were permitted to increase their dose of study medica-
tion (oxycodone PR component) up to 120 mg/day dur-
ing the double-blind phase. Since the studies were
double-dummy, oxycodone PR placebo was given to
patients in the combination treatment group, and oxy-
codone PR/naloxone PR placebo was given to those in
the oxycodone PR alone treatment group.
Efficacy assessments
Efficacy data were collected in daily diaries and during
eight site visits. The primary efficacy variable was the
Pain Intensity Scale [37] that assesses patients’ pain on
an 11-point ordinal scale (0 = no pain, 10 = pain as
bad as you can imagine). Secondary endpoints included
frequency of rescue medication administration (oxyco-
done immediate-release [IR], prescribed every 4 hours
as needed), patient diary assessment of laxatives
Figure 1 Study design. PR = prolonged-release.
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blind phase and a patient bowel function self-
assessment using the validated BFI [29]. The BFI is
rated as the mean score on the following items: ease of
defecation (0-100; 0 = easy/no difficulty, 100 = severe
difficulty), feeling of incomplete bowel evacuation
(0-100; 0 = not at all, 100 = very strong), and judg-
ment of constipation (0-100; 0 = not at all, 100 = very
strong). Exploratory endpoints included the SF-36
health survey and the TSQM, which assess general
health and patient satisfaction, respectively.
Safety assessments
Safety assessments consisted of monitoring and record-
ing all AEs and serious AEs (SAEs), and monitoring
haematology, blood chemistry, urine values and vital
signs, and performing physical examinations.
Statistical analysis
The full analysis population consisted of those patients
who were randomised and received at least one dose of
study medication during the double-blind phase and
who had at least one double-blind assessment of the pri-
mary efficacy variable. The per-protocol population
included those patients without any major protocol
deviations, while the safety population included all
randomised patients who received any study medication
and who had at least one post-baseline safety
assessment.
The primary efficacy variable was analyzed within a
mixed model repeated measurements (MMRM) analysis.
The MMRM analysis included terms for study, treat-
ment, time as categorical variables, and pre-randomisa-
tion pain at the end of the titration period and subject
as random effects. The primary comparison was the
non-inferiority analysis between oxycodone PR/naloxone
PR and oxycodone PR, at a one-sided 2.5% level of sig-
nificance. Two-sided 95% confidence intervals (CIs)
between oxycodone PR/naloxone PR and oxycodone PR
were calculated for the per-protocol and full analysis
populations. The primary comparison was based on the
per-protocol population and non-last observation car-
ried forward (non-LOCF; i.e. observed cases) and con-
firmed using the full analysis population with LOCF and
non-LOCF.
Secondary efficacy variables included the BFI, which
was analyzed via the same methods as the primary end-
point. Descriptive statistics were used to describe the
frequency of rescue medication intake and the number
of patients taking laxatives during the entire or first 4
weeks of the double-blind phase. The treatment groups
were compared using Fisher’s exact test for the number
of patients taking laxatives during the first 4 weeks of
the double-blind phase.
The patient incidence (%) and number of reports of
treatment-emergent AEs were calculated and presented
for each treatment using MedDRA preferred term and
body system. Absolute values and changes to baseline of
vital signs and laboratory parameters were analyzed
using descriptive statistics.
Results
859 patients were enrolled in the two studies, of these
587 patients were randomised to treatment in the dou-
ble-blind phase and were included in the safety analysis;
581 patients received at least one dose of study medica-
tion and were included in the full analysis population.
499 patients (85%) completed the studies, of which 429
qualified for the per-protocol population (Figure 2).
Similar rates of study drug discontinuation were
observed in the two treatment groups: 16.3 and 13.7%,
respectively, in the oxycodone PR/naloxone PR and the
oxycodone PR groups. The main reason for early dis-
continuation was AEs (Figure 2).
All patients reported moderate/severe chronic non-
malignant pain requiring continuous opioid therapy,
with constipation caused or aggravated by an opioid.
The majority of patients was pre-treated with WHO III
opioids and received individual laxative regimen. After
the switch to the standard laxative regimen (oral bisca-
codyl), doses of bisacodyl were 10 mg per intake. How-
ever, investigators instructed their subjects that, if they
experienced discomfort during the 72 hour period, they
could take bisacodyl as a laxative within 72 hours of
their most recent bowel movement, as required, to treat
constipation. At the discretion of the Investigator, the
bisacodyl dose could be lowered (to 5 mg) if either the
investigator or the subject felt that dose was sufficient
to provide adequate bowel movement.
The majority of patients (86%) presented with pain
associated with musculoskeletal and connective tissue
disorders; the most frequent conditions were back pain,
osteoarthritis and intervertebral disc disorders. Many
patients (34%) reported neuropathic pain e.g. neuralgia,
sciatica and cervicobrachial syndrome and the presence
of more than one type of chronic pain was possible.
There were no differences in patient demographics
between the two treatment groups; although there were
more females than males in the studies, the ratio of
women to men was similar in the two patient groups
(Table 1).
Efficacy evaluation
The primary objective was to demonstrate the non-
inferiority of oxycodone PR/naloxone PR to oxycodone
PR alone for analgesic efficacy (average pain over the
previous 24 hours), as assessed using the Pain Intensity
Scale. Efficacy analysis was based on the per-protocol
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double-blind phase (Visit 3 to Visit 8) mean Pain Inten-
sity Scale scores remained stable, with no statistically
significant difference in analgesic efficacy observed
between the two treatment groups (p = 0.3197; non-
inferiority p < 0.0001; 95% CI -0.07, 0.23; Table 2). This
indicated that oxycodone PR/naloxone PR was non-
inferior to oxycodone PR. Non-inferiority for the mean
Pain Intensity Scale scores was confirmed in the full
analysis population (p = 0.9042; non-inferiority p <
0.0001; 95% CI -0.14, 0.13; LOCF) and (p = 0.8779;
non-inferiority p < 0.0001; 95% CI -0.15, 0.13; non-
LOCF). Furthermore, the majority of patients (77%) con-
tinued on the same dose of study medication from the
time of randomisation to the end of the double-blind
phase; in each treatment group, 65 patients were up-
titrated and three were down-titrated. The mean (SD)
daily supplemental analgesic use was 0.5 (0.63) uses in
the oxycodone PR group and 0.6 (0.65) in the oxyco-
done PR/naloxone PR group between Days 1-28. During
Days 57-84, the mean (SD) supplemental analgesic use
was 0.4 (0.61) in the oxycodone PR group and 0.4 (0.58)
in the oxycodone PR/naloxone PR group. There was no
statistically significant difference in mean daily use of
supplemental rescue analgesic medication between those
treated with oxycodone PR/naloxone PR or those who
received oxycodone PR for the both the per-protocol
(treatment difference: -0.05; p = 0.39; 95% CI -0.15,
0.06) and full analysis populations (treatment differ-
ence:-0.05; p = 0.3386; 95% CI -0.14, 0.05).
A secondary objective of the study was to assess
symptoms of constipation. At baseline (Visit 3), bowel
function, assessed using the BFI, was comparable
between the two treatment groups (Figure 3). Subse-
quently, statistically significant and clinically relevant
improvements [29] in the oxycodone PR/naloxone PR
group were observed by Week 1 (Visit 4) and at every
subsequent time point during the 12-week, double-
blind study period (-15.1; p < 0.0001; CI -17.3, -13.0;
Figure 3).
Occurrence of constipation was also assessed by con-
sidering the number of patients taking laxatives. Patients
treated with oxycodone PR/naloxone PR had a signifi-
cantly lower laxative intake than patients who received
oxycodone PR alone (p < 0.0001) and, during the first 4
weeks of the double-blind period, significantly fewer
patients treated with oxycodone PR/naloxone PR
required laxatives compared to the oxycodone PR group
(36.5 vs 59.0%, respectively; p < 0.0001).
There were no notable differences in SF-36 scores
between the two treatment groups, including the SF-36-
Bodily Pain subscale, at Visits 2 and 8 (Week 12).
During the 12-week, double-blind period, there were no
significant differences in TSQM scores for those patients
who received oxycodone PR/naloxone PR or oxycodone
PR.
Figure 2 Patient disposition. PR = prolonged-release.
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Overall, the incidence of AEs was similar between the
groups (Table 3), with a total of 61.0 and 57.3% of
patients experiencing AEs with oxycodone PR/naloxone
PR and oxycodone PR alone, respectively. The number
of patients experiencing AEs related to study medication
was similar between the two groups (31.9 and 36.0%
with oxycodone PR/naloxone PR and oxycodone PR
alone, respectively). A similar number of patients dis-
continued because of AEs in the oxycodone PR and oxy-
codone/naloxone PR groups (6.4 and 4.8% respectively),
and there were no deaths during the study.
The most common AEs were GI (21.3% in the total
group). Infections and infestations (17.5%), nervous sys-
tem disorders (12.8%), musculoskeletal and connective
tissue disorders (12.4%), and general disorders (10.2%)
were the other most common AEs. Nausea, diarrhoea
and abdominal pain were the most frequently reported
GI AEs across both groups (Table 3). Constipation (only
worsening of existing condition observed prior to rando-
misation) was reported in more patients treated with
oxycodone PR (3.4%) than in those who received oxyco-
done PR/naloxone PR (0.7%). Overall, there was a low
incidence of diarrhoea (4.4% in the total group), with
comparable numbers of patients experiencing this in
both treatment groups (Table 3). Cases of diarrhoea
were generally transient (mean duration 5.81 days).
The incidence of severe AEs (9.9 and 10.8% in the
oxycodone PR/naloxone PR and oxycodone PR groups,
respectively) and SAEs (4.5 and 4.4%, in the oxycodone
PR/naloxone PR and oxycodone PR groups, respectively)
was low with both treatments. However, there was a
slightly higher incidence of study drug-related SAEs in
the oxycodone PR/naloxone PR group than in the
Table 1 Patient demographics at baseline (Safety population)
Oxycodone PR
(n = 295)
Oxycodone PR/naloxone PR
(n = 292)
Total
(n = 587)
Age (years) Mean (SD) 58.3 (11.52) 57.5 (11.27) 57.9 (11.40)
Median 58 58 58
Min, Max 25, 87 29, 84 25, 87
Age group, n (%) ≤65 216 (73.2) 221 (75.7) 437 (74.4)
>65 79 (26.8) 71 (24.3) 150 (25.6)
Sex, n (%) Male 108 (36.6) 102 (34.9) 210 (35.8)
Female 187 (63.4) 190 (65.1) 377 (64.2)
Race, n (%) Caucasian 293 (99.3) 292 (100.0) 585 (99.7)
Black 1 (0.3) 0 (0.0) 1 (0.2)
Other 1 (0.3) 0 (0.0) 1 (0.2)
Weight (kg) Mean (SD) 84.7 (20.52) 84.2 (18.03) 84.4 (19.31)
Median 83 80.6 82
Min, Max 44, 174 47.5, 147 44, 174
PR = prolonged-release; SD = standard deviation.
Table 2 Mean pain intensity over the previous 24 hours
at each study visit (per-protocol population; non-last
observation carried forward analysis)
Name (visit) Pain Intensity Scale score
Oxycodone
PR
Oxycodone/
Naloxone PR
Total
Randomisation
(Visit 3)
N 208 221 429
Mean
(SD)
3.3 (0.97) 3.4 (1.07) 3.4
(1.02)
Median 3.0 3.0 3.0
Min,
Max
0.0, 7.0 0.0, 9.0 0.0, 9.0
Week 1
(Visit 4)
N 208 220 428
Mean
(SD)
3.5 (1.3) 3.6 (1.51) 3.6
(1.41)
Median 3.0 4.0 4.0
Min,
Max
0.0, 7.0 0.0, 9.0 0.0, 9.0
Week 4
(Visit 6)
N 208 220 428
Mean
(SD)
3.5 (1.37) 3.5 (1.51) 3.5
(1.44)
Median 3.0 4.0 3.5
Min,
Max
0.0, 7.0 0.0, 9.0 0.0, 9.0
Week 12
(Visit 8)
N 204 220 424
Mean
(SD)
3.5 (1.53) 3.6 (1.78) 3.6
(1.67)
Median 4.0 4.0 4.0
Min,
Max
0.0, 8.0 0.0, 9.0 0.0, 9.0
Min = minimum; Max = maximum; PR = prolonged-release; SD = standard
deviation.
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Three patients (1.0%) in the oxycodone PR group had
AEs related to opioid withdrawal, however this was
observed in only one patient (0.3%) in the oxycodone
PR/naloxone PR group.
Analyses of the mean change in haematology and
blood chemistry revealed no changes of clinical concern.
Vital signs, including systolic and diastolic blood pres-
sure and pulse rate, were within the normal range at
screening and end of study in both treatment groups.
There was no change in body weight in either treatment
group during the 12-week study.
Discussion
The results of this prospectively designed pooled analy-
sis demonstrate that during a 12-week period, in this
population, oxycodone PR/naloxone PR (20-120 mg/
day) provides analgesia that is as effective as oxycodone
Figure 3 Mean Bowel Function Index score over time (full
analysis population; last observation carried forward analysis).
Table 3 Incidence of adverse events by organ class (≥10%) and preferred term (≥1%; Safety population)
Oxycodone PR n = 295
n (%)
Oxycodone/naloxone PR n = 292
n (%)
Total
n = 587
n (%)
Gastrointestinal disorders 64 (21.7) 61 (20.9) 125 (21.3)
Dry mouth 3 (1.0) 3 (1.0) 6 (1.0)
Diarrhoea 11 (3.7) 15 (5.1) (26) 4.4
Constipation 10 (3.4) 2 (0.7) 12 (2.0)
Upper abdominal pain 4 (1.4) 6 (2.1) 10 (1.7)
Abdominal pain 7 (2.4) 11 (3.8) 18 (3.1)
Vomiting 8 (2.7) 5 (1.7) 13 (2.2)
Nausea 25 (8.5) 23 (7.9) 48 (8.2)
General disorders and administrative site conditions 26 (8.8) 34 (11.6) 60 (10.2)
Pain 5 (1.7) 9 (3.1) 14 (2.4)
Peripheral oedema 4 (1.4) 5 (1.7) 9 (1.5)
Fatigue 7 (2.4) 6 (2.1) 13 (2.2)
Chills 3 (1.0) 5 (1.7) 8 (1.4)
Infections and infestations 56 (19.0) 47 (16.1) 103 (17.5)
Nasopharyngitis 10 (3.4) 4 (1.7) 103 (17.5)
Lower respiratory tract infection 3 (1.0) 3 (1.0) 6 (1.0)
Gastroenteritis 7 (2.4) 5 (1.7) 12 (2.0)
Bronchitis 3 (1.0) 3 (1.0) 6 (1.0)
Urinary tract infection 6 (2.0) 13 (4.5) 19 (3.2)
Musculoskeletal and connective tissue disorders 34 (11.5) 39 (13.4) 73 (12.4)
Back pain 9 (3.1) 11 (3.8) 20 (3.4)
Arthralgia 5 (1.7) 6 (2.1) 11 (1.9)
Myalgia 2 (0.7) 4 (1.4) 6 (1.0)
Nervous system disorders 35 (11.9) 40 (13.7) 75 (12.8)
Sciatica 1 (0.3) 6 (2.1) 7 (1.2)
Headache 11 (3.7) 12 (4.1) 23 (3.9)
Dizziness 10 (3.4) 5 (1.7) 15 (2.6)
PR = prolonged-release.
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done PR/naloxone PR versus oxycodone PR in mean
Pain Intensity Scale and a low and comparable use of
supplemental analgesic medication in both treatment
groups. Furthermore, patients receiving oxycodone PR/
naloxone PR demonstrated statistically and clinically sig-
nificant improvements in bowel function. Oxycodone
PR/naloxone PR was superior to oxycodone PR with
regard to bowel function, particularly in reducing consti-
pation. There was also a significantly reduced use of
laxatives in the first 4 weeks of the study in patients
who received oxycodone PR/naloxone PR compared
with those who received oxycodone PR alone.
The incidence of AEs was comparable in both treat-
ment groups; a similar number of patients in each
group discontinued the study because of AEs. The most
frequently reported AEs were GI. However, importantly,
the incidence of diarrhoea was generally low, transient
and comparable between treatment groups. After the
administration of oxycodone PR/naloxone PR there
were no additional or unexpected risks observed when
compared with oxycodone PR treatment. Consequently,
the risk/benefit ratio was more favourable for oxycodone
PR/naloxone PR compared with oxycodone PR alone in
this group of patients.
Two exploratory endpoints (SF-36 and TSQM)
showed that there were no differences in quality of life
scores between the two groups. These questionnaires
measure general health and treatment satisfaction and
do not specifically assess pain-related quality of life.
However, it can be assumed that patients’ responses to
these assessments are strongly influenced by pain.
Therefore, the comparable scores indicate a similar
analgesic efficacy for oxycodone PR/naloxone PR.
One of the main limitations of this analysis was that
clinical efficacy and tolerability can only be discussed
for the dose ranges used. Further studies are required to
establish the clinical benefits of other doses and to
assess longer-term effects of oxycodone PR/naloxone PR
combination treatment for patients with chronic pain.
Conclusions
This pooled analysis demonstrated the non-inferiority of
oxycodone PR/naloxone PR compared with oxycodone
PR alone for analgesic efficacy in patients with moder-
ate-to-severe non-malignant pain treated for 12 weeks.
The oxycodone PR/naloxone PR formulation improved
bowel function and significantly reduced constipation in
these patients.
List of abbreviations
AE: adverse event; BFI: Bowel Function Index; CIs: confidence intervals; FDC:
fixed-dose combination; GI: gastrointestinal; IR: immediate release; Non-LOCF:
non-last observation carried forward; OIC: Opioid-induced constipation; PR:
prolonged release; SAE: serious adverse event; TSQM: Treatment Satisfaction
Questionnaire for Medication; WHO: World Health Organisation
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
This study was funded by Mundipharma Research GmbH & Co. KG.
PL, MH, BB and KR are employed by Mundipharma Research GmbH & Co.
KG at the time of the study conduct and article drafting. OL and MB were
involved as investigators in the clinical study reported here. KHS has
received honoraria from medical device and pharmaceutical companies for
lectures at conferences, to attend advisory boards, to contribute to
publications and to support professional development, e.g. attendance at
meetings. KHS is a member of the Leeds Pallium Research Group that has
received research funding from medical device and pharmaceutical
companies for clinical research. EAL has received honoraria for lectures from
Mundipharma, Gruenenthal, Wyeth and Pfizer. All authors were involved in
the development, critical reviewing and approval of this manuscript.
Acknowledgements
The authors would like to thank Diya Lahiri, PhD, Medicus International, for
her editorial assistance. This study was funded by Mundipharma Research
GmbH & Co. KG.
Author details
1Schmerzpraxis, Rheinstrasse, Mainz, Germany.
2Mundipharma Research
GmbH & Co. KG, Hoehenstrasse, Limburg (Lahn), Germany.
3Klinik für
Schmerz- und Palliativmedizin, Klinikum St. Marien-Hospital Lünen,
Altstadtstrasse, Lünen, Germany.
4Avondale Surgery, Chesterfield, Avondale
Road, Derbyshire, UK.
5Leeds Teaching Hospital, Glebe House, Scholes Lane,
Leeds, UK.
6University Witten/Herdecke, Alfred-Herrhausen-Straße, Witten,
Germany.
Received: 6 March 2010 Accepted: 29 September 2010
Published: 29 September 2010
References
1. Ventafridda V, Saita L, Ripamonti C, De Conno F: WHO guidelines for the
use of analgesics in cancer pain. Int J Tissue React 1985, 7:93-96.
2. Coluzzi F, Pappagallo M: Opioid therapy for chronic noncancer pain:
practice guidelines for initiation and maintenance of therapy. Minerva
Anestesiol 2005, 71:425-433.
3. Coluzzi F, Mattia C: Oxycodone. Pharmacological profile and clinical data
in chronic pain management. Minerva Anestesiol 2005, 71:451-460.
4. Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L,
Weinstein SM, Kaiko RF, Buckley BJ, Reder RF: Controlled-release
oxycodone compared with controlled-release morphine in the treatment
of cancer pain: a randomized, double-blind, parallel-group study. Eur J
Pain 1998, 2:239-249.
5. Kalso E: Oxycodone. J Pain Symptom Manage 2005, 29:S47-S56.
6. Gimbel JS, Richards P, Portenoy RK: Controlled-release oxycodone for pain
in diabetic neuropathy: a randomized controlled trial. Neurology 2003,
60:927-934.
7. Watson CP, Babul N: Efficacy of oxycodone in neuropathic pain: a
randomized trial in postherpetic neuralgia. Neurology 1998, 50:1837-1841.
8. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J: Controlled-
release oxycodone relieves neuropathic pain: a randomized controlled
trial in painful diabetic neuropathy. Pain 2003, 105:71-78.
9. Kurz A, Sessler DI: Opioid-induced bowel dysfunction: pathophysiology
and potential new therapies. Drugs 2003, 63:649-671.
10. Pappagallo M: Incidence, prevalence, and management of opioid bowel
dysfunction. Am J Surg 2001, 182:11S-18S.
11. Ballantyne JC: Opioid analgesia: perspectives on right use and utility. Pain
Physician 2007, 10:479-491.
12. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R: The
prevalence, severity, and impact of opioid-induced bowel dysfunction:
results of a US and European Patient Survey (PROBE 1). Pain Med 2009,
10:35-42.
Löwenstein et al. BMC Clinical Pharmacology 2010, 10:12
http://www.biomedcentral.com/1472-6904/10/12
Page 8 of 913. Choi YS, Billings JA: Opioid antagonists: a review of their role in palliative
care, focusing on use in opioid-related constipation. J Pain Symptom
Manag 2002, 24:71-90.
14. Sykes NP: An investigation of the ability of oral naloxone to correct
opioid-related constipation in patients with advanced cancer. Palliat Med
1996, 10:135-44.
15. Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K: Oral naloxone
reverses opioid-associated constipation. Pain 2000, 84:105-109.
16. Liu M, Wittbrodt E: Low-dose oral naloxone reverses opioid-induced
constipation and analgesia. J Pain Symptom Manage 2002, 23:48-53.
17. Latasch L, Zimmermann M, Eberhardt B, Jurna I: Treatment of morphine-
induced constipation with oral naloxone. Anaesthesist 1997, 46:191-194.
18. Meissner W, Leyendecker P, Hopp M, Bosse B, Nichols T, Reimer K: Long-
term efficacy and safety of oxycodone and naloxone in a prolonged-
release fixed combination tablet in patients with moderate to severe
chronic pain. WIP, World Institute of Pain, New York 2009, Abstract number:
A-118-0027-00784.
19. Vondrackova D, Leyendecker P, Meissner W, Hopp M, Szombati I,
Hermanns K, Ruckes C, Weber S, Grothe B, Fleischer W, Reimer K: Analgesic
efficacy and safety of oxycodone in combination with naloxone as
prolonged release tablets in patients with moderate to severe chronic
pain. JP a i n2008, 9:1144-1154.
20. Smith K, Hopp M, Mundin G, Leyendecker P, Bailey P, Grothe B, Uhl R,
Reimer K: Single- and multiple-dose pharmacokinetic evaluation of
oxycodone and naloxone in an opioid agonist/antagonist prolonged-
release combination in healthy adult volunteers. Clin Ther 2008,
30:2051-2068.
21. Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M,
Ruckes C, Wirz S, Fleischer W, Reimer K: A randomised controlled trial with
prolonged-release oral oxycodone and naloxone to prevent and reverse
opioid-induced constipation. Eur J Pain 2009, 13:56-64.
22. Sander-Kiesling A, Leyendecker P, Hopp M, Tarau L, Lejcko J, Meissner W,
Sevcik P, Hakl M, Hrib R, Uhl R, Dürr H, Reimer K: Long-term efficacy and
safety of combined prolonged-release oxycodone and naloxone in the
management of non-cancer chronic pain. Int J Clin Pract 2010, 64:763-774.
23. Nadstawek J, Leyendecker P, Hopp M, Wirz S, Ruckes C, Fleischer W,
Reimer K: Patient assessment of a novel therapeutic approach for the
treatment of severe, chronic pain. Int J Clin Pract 2008, 62:1159-1167.
24. Nolte T: Prolonged-release oxycodone/naloxone is effective and safe in
clinical use. Pall Med 2008, 22(Suppl):399-565, Poster 275.
25. Clemens KE, Quednau I, Klaschik E: Bowel function during therapy with a
combination of oxycodone/naloxone prolonged-release tablets in
generic patients. 11th EAPC Congress, Vienna 2009, Poster number F317.
26. Lux EA, Leyendecker P, Kremers W, Bosse B, Hopp M, Reimer K: Efficacy
and safety of oxycodone and naloxone in a prolonged release fixed
combination tablet in elderly patients (> 65 years) with moderate to
severe chronic pain. 19th IAGG Congress, Paris 2009, Abstract number PB7
475.
27. Löwenstein O, Leyendecker P, Hopp M, Schutter U, Rogers PD, Uhl R,
Bond S, Kremers W, Nichols T, Krain B, Reimer K: Combined prolonged-
release oxycodone and naloxone improves bowel function in patients
receiving opioids for moderate-to-severe non-malignant chronic pain - a
randomised controlled trial. Expert Opin Pharmacother 2009, 10:531-543.
28. Simpson K, Leyendecker P, Hopp M, Müller-Lissner S, Löwenstein O, De
Andrés J, Troy Ferrarons J, Ruckes C, Krain B, Olway H, Nichols T, Kremers W,
Reimer K: Fixed-ratio combination oxycodone/naloxone compared with
oxycodone alone for the relief of opioid-induced constipation in
moderate-to-severe noncancer pain. Curr Med Res Opin 2008,
24:3503-3512.
29. Rentz AM, Ren Y, Müller-Lissner S, Leyendecker P: Validation of the Bowel
Function Index to detect clinically meaningful changes in opioid
induced constipation. J Med Economics 2009, 12:371-383.
30. Ware J: SF-36 Health Survey Manual & Interpretation Guide. Boston:
Nimrod Press 1993.
31. Ware J, Kosinski M, Dewey JE: How to score version 2 of the SF-36 Health
Survey. Lincoln, RI: Quality Metric Incorporated 2000.
32. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR:
Validation of a general measure of treatment satisfaction, the Treatment
Satisfaction Questionnaire for Medication (TSQM), using a national panel
study of chronic disease. Health Qual Life Outcomes 2004, 2:12.
33. World-Medical-Association-Declaration-of-Helsinki: Ethical principles for
medical research involving human subjects 2002.
34. International Conference on Harmonization (ICH): Guidelines on Good
Clinical Practice 1997.
35. European Parliament and Council of the European Union: Clinical Trials
Directive 2001/20/EC. Official Journal of the European Communities 2001,
121:34-44.
36. Drossman DA: The functional gastrointestinal disorders and the Rome II
process. Gut 1999, 45(Suppl II):II1-6.
37. Cleeland CS, Ryan KM: Pain assessment: global use of the Brief Pain
Inventory. Ann Acad Med Singapore 1994, 23:129-138.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6904/10/12/prepub
doi:10.1186/1472-6904-10-12
Cite this article as: Löwenstein et al.: Efficacy and safety of combined
prolonged-release oxycodone and naloxone in the management of
moderate/severe chronic non-malignant pain: results of a prospectively
designed pooled analysis of two randomised, double-blind clinical
trials. BMC Clinical Pharmacology 2010 10:12.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Löwenstein et al. BMC Clinical Pharmacology 2010, 10:12
http://www.biomedcentral.com/1472-6904/10/12
Page 9 of 9